Chronic myelogenous leukemia

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Chronic myelogenous leukemia is a clonal hematopoietic stem disorder characterized by excess numbers of myeloid cells that over time, lose the capacity for terminal differentiation. A series of discoveries led to the identification of the BCR-ABL tyrosine kinase as the cause of the disease and this provided the impetus for the development of specific agents that target this abnormality. This has also led to improved methods for diagnosis and molecular monitoring of patients with the disease.

Original languageEnglish (US)
Title of host publicationPrinciples of Molecular Medicine
PublisherHumana Press
Pages789-793
Number of pages5
ISBN (Print)9781588292025
DOIs
StatePublished - 2006

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Physiologic Monitoring
Myeloid Cells
Protein-Tyrosine Kinases

Keywords

  • Allogeneic stem cell transplant
  • BCR-ABL
  • chronic myelogenous leukemia
  • imatinib
  • molecular monitoring
  • Philadelphia chromosome
  • RT-PCR
  • tyrosine kinase
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Druker, B. (2006). Chronic myelogenous leukemia. In Principles of Molecular Medicine (pp. 789-793). Humana Press. https://doi.org/10.1007/978-1-59259-963-9_81

Chronic myelogenous leukemia. / Druker, Brian.

Principles of Molecular Medicine. Humana Press, 2006. p. 789-793.

Research output: Chapter in Book/Report/Conference proceedingChapter

Druker, B 2006, Chronic myelogenous leukemia. in Principles of Molecular Medicine. Humana Press, pp. 789-793. https://doi.org/10.1007/978-1-59259-963-9_81
Druker B. Chronic myelogenous leukemia. In Principles of Molecular Medicine. Humana Press. 2006. p. 789-793 https://doi.org/10.1007/978-1-59259-963-9_81
Druker, Brian. / Chronic myelogenous leukemia. Principles of Molecular Medicine. Humana Press, 2006. pp. 789-793
@inbook{c16523e5feb043babebadf3aac89c42f,
title = "Chronic myelogenous leukemia",
abstract = "Chronic myelogenous leukemia is a clonal hematopoietic stem disorder characterized by excess numbers of myeloid cells that over time, lose the capacity for terminal differentiation. A series of discoveries led to the identification of the BCR-ABL tyrosine kinase as the cause of the disease and this provided the impetus for the development of specific agents that target this abnormality. This has also led to improved methods for diagnosis and molecular monitoring of patients with the disease.",
keywords = "Allogeneic stem cell transplant, BCR-ABL, chronic myelogenous leukemia, imatinib, molecular monitoring, Philadelphia chromosome, RT-PCR, tyrosine kinase, tyrosine kinase inhibitors",
author = "Brian Druker",
year = "2006",
doi = "10.1007/978-1-59259-963-9_81",
language = "English (US)",
isbn = "9781588292025",
pages = "789--793",
booktitle = "Principles of Molecular Medicine",
publisher = "Humana Press",

}

TY - CHAP

T1 - Chronic myelogenous leukemia

AU - Druker, Brian

PY - 2006

Y1 - 2006

N2 - Chronic myelogenous leukemia is a clonal hematopoietic stem disorder characterized by excess numbers of myeloid cells that over time, lose the capacity for terminal differentiation. A series of discoveries led to the identification of the BCR-ABL tyrosine kinase as the cause of the disease and this provided the impetus for the development of specific agents that target this abnormality. This has also led to improved methods for diagnosis and molecular monitoring of patients with the disease.

AB - Chronic myelogenous leukemia is a clonal hematopoietic stem disorder characterized by excess numbers of myeloid cells that over time, lose the capacity for terminal differentiation. A series of discoveries led to the identification of the BCR-ABL tyrosine kinase as the cause of the disease and this provided the impetus for the development of specific agents that target this abnormality. This has also led to improved methods for diagnosis and molecular monitoring of patients with the disease.

KW - Allogeneic stem cell transplant

KW - BCR-ABL

KW - chronic myelogenous leukemia

KW - imatinib

KW - molecular monitoring

KW - Philadelphia chromosome

KW - RT-PCR

KW - tyrosine kinase

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84890541877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890541877&partnerID=8YFLogxK

U2 - 10.1007/978-1-59259-963-9_81

DO - 10.1007/978-1-59259-963-9_81

M3 - Chapter

AN - SCOPUS:84890541877

SN - 9781588292025

SP - 789

EP - 793

BT - Principles of Molecular Medicine

PB - Humana Press

ER -